(CORT) Corcept Therapeutics Incorporated Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CORT) Corcept Therapeutics Incorporated Complete Analysis Pack
Visual. Strategic. Downloadable.
This Corcept Therapeutics Incorporated 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategies and shows how its offering is used in treating Cushing’s syndrome and related indications; the page includes a real preview/sample of the analysis so you can review style and content before buying—purchase the full version to get the complete ready-to-use report.
Product
1 marketed drug: Korlym
Korlym, the only marketed drug in Corcept Therapeutics Incorporated’s portfolio, contains mifepristone and is the company’s core revenue engine. In Corcept Therapeutics Incorporated’s latest reported results, net product revenue was driven almost entirely by Korlym, which keeps the brand at the center of the 4P mix. The 300 mg tablet gives Corcept Therapeutics Incorporated a clear, focused market position.
Once-daily oral tablets
Korlym is a once-daily oral tablet, so patients take 1 dose per day at home instead of receiving hospital-based treatment. That fits chronic Cushing's syndrome care, where long-term outpatient use matters more than short stays, and it supports steady adherence in a daily routine.
Endogenous Cushing’s syndrome
Korlym is Corcept Therapeutics Incorporated’s prescription therapy for adults with endogenous Cushing’s syndrome, a rare hypercortisolism-related endocrine disease. It serves a small patient pool with limited treatment options, which keeps the product tightly focused on specialist care. In Corcept Therapeutics Incorporated’s mix, the product is defined by this orphan-style need and its role in controlling excess cortisol.
Hyperglycemia and glucose intolerance
Corcept Therapeutics Incorporated targets hyperglycemia and glucose intolerance in patients with hypercortisolism, a key fit for people with type 2 diabetes or prediabetes. Cortisol excess drives insulin resistance, and metabolic problems affect up to 70% of patients with Cushing syndrome, so the clinical need is clear.
- Used for cortisol-driven glucose issues
- Best fit in type 2 diabetes risk
- Targets metabolic complications
Pipeline: relacorilant and oncology programs
Corcept Therapeutics Incorporated’s pipeline is led by relacorilant, a late-stage cortisol modulator for Cushing’s syndrome, a disorder that affects about 40,000 people in the United States. The same asset is being tested with nab-paclitaxel in ovarian tumors and other cortisol-excess settings, so it can support both rare-disease and oncology growth.
Beyond relacorilant, Corcept Therapeutics Incorporated is studying programs in metastatic castration-resistant prostate cancer, antipsychotic-induced weight gain, and FKBP5 assays. That mix widens the product base and gives the company more shots at future revenue, while keeping the core focus on cortisol biology.
- Relacorilant is the lead pipeline asset.
- Ovarian tumor studies use nab-paclitaxel.
- Pipeline spans rare disease and oncology.
- Target markets include prostate cancer and weight gain.
Korlym Drives Corcept, with Relacorilant Expanding the Pipeline
Corcept Therapeutics Incorporated’s Product mix is highly concentrated: Korlym is the only marketed drug and the main revenue driver, with a once-daily 300 mg oral tablet design that fits chronic outpatient care for endogenous Cushing’s syndrome. The pipeline is led by relacorilant, which extends the cortisol-focused product base into late-stage rare disease and oncology.
| Product | Role | Key fact |
|---|---|---|
| Korlym | Core marketed product | Only approved drug; once-daily oral tablet |
| Relacorilant | Lead pipeline asset | Late-stage cortisol modulator |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Corcept Therapeutics’ product, pricing, place, and promotion strategies with real-world market context.
Editable Excel File
Distills Corcept Therapeutics’ 4Ps into a clear snapshot, making complex marketing strategy easy to grasp and discuss fast.
Reference Sources
Consolidates primary industry reports, clinical data, SEC filings, and trusted benchmarks to validate Corcept Therapeutics’ market, pricing, and competitive assumptions.
Place
U.S. commercial market
Corcept Therapeutics Incorporated keeps its place strategy tightly centered on the U.S. commercial market: Korlym is sold domestically through a specialty-drug channel, not a broad global retail network. That means access runs through U.S. prescribers, specialty pharmacies, and payer coverage, so distribution, reimbursement, and patient support drive sales more than geography.
Prescription-only access
Korlym is available only through physicians, so patients must get a prescription before use. That keeps Corcept Therapeutics Incorporated in a managed medical channel, not over-the-counter retail, and it helps control diagnosis, dosing, and follow-up for a niche endocrine therapy.
Specialist prescribers
Corcept Therapeutics’ therapy is mainly prescribed by endocrinologists, because Cushing’s syndrome affects only about 40,000-50,000 people in the U.S. and often needs cortisol-focused care. These specialists handle complex metabolic issues, so access to them is key for diagnosis and treatment. For Corcept, reaching a small, high-need prescriber base supports targeted use and efficient uptake.
Clinic and hospital settings
Corcept Therapeutics Incorporated reaches patients mainly through specialty endocrine clinics and hospital treatment centers, where rare disorders like Cushing’s syndrome are diagnosed and managed. With U.S. prevalence estimated at about 40,000 patients, these sites are key for non-surgical candidates who need long-term medical therapy.
- Specialty clinics drive diagnosis
- Hospitals manage complex cases
- Supports non-surgical access
Menlo Park headquarters
Corcept Therapeutics Incorporated is headquartered in Menlo Park, California, and its commercial and development work is run from the U.S. West Coast. That setup keeps product launch, medical affairs, and pipeline execution close to leadership, which matters for a company that reported 2025 net revenue in the hundreds of millions and is still scaling its U.S. franchise.
- Menlo Park base supports fast U.S. decisions
- West Coast hub links sales and R&D
- Helps coordinate launch and medical affairs
Corcept’s Specialty Channel Drives Korlym Access in a Rare U.S. Market
Corcept Therapeutics Incorporated uses a U.S.-only, specialty-drug place model for Korlym, so access runs through endocrinologists, specialty pharmacies, and payer approval. This fits a rare disease with about 40,000 to 50,000 U.S. patients and keeps distribution tightly managed. In 2025, that channel supported a net revenue base in the hundreds of millions.
| Place factor | Detail |
|---|---|
| Market | U.S. only |
| Channel | Specialty pharmacy |
| Prescribers | Endocrinologists |
| Patient base | 40,000-50,000 |
Full Version Awaits
Corcept Therapeutics Incorporated Reference Sources
The preview shown here is the actual Corcept Therapeutics 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable marketing analysis you’ll download immediately after checkout, fully complete and ready to use.
Promotion
Rare-disease medical promotion
Corcept Therapeutics promotes Korlym for hyperglycemia secondary to endogenous Cushing’s syndrome, a rare endocrine disorder with an estimated incidence of 1.2 to 2.4 cases per million people each year. The message focuses on cortisol excess and is aimed at endocrinologists and other specialists, not broad consumer audiences. That narrow, physician-led approach fits a small, high-need market where diagnosis and treatment are complex.
Scientific data presentations
Corcept Therapeutics Incorporated leans on scientific data presentations to build awareness for "Korlym" and "relacorilant," showing trial results in medical congresses and peer-reviewed settings. This evidence-led promotion matters in prescription drugs because physicians base use on efficacy and safety data, not ads. In 2025, Corcept kept focus on clinical-stage data to support future label expansion.
Medical congress visibility
Corcept can use endocrinology and oncology congresses to reach the doctors most likely to prescribe its therapies, and to present new efficacy and safety data from ongoing trials. These meetings matter because peer-reviewed podium and poster updates can speed awareness of the pipeline. In 2024, Corcept reported $675.8 million in revenue, showing it already has scale to support conference-driven promotion.
Investor and corporate communications
Corcept Therapeutics uses earnings releases, SEC filings, and pipeline updates to keep investors aligned with clinical progress and key milestones. In its latest reported year, the Company posted $611.6 million in revenue, showing why clear market communication matters for credibility and valuation. These updates help frame trial progress, cash use, and execution risk.
- Regular earnings and SEC updates
- Shares clinical milestones clearly
- Supports credibility with investors
Patient and physician education
Corcept Therapeutics uses patient and physician education as a core promotion tool, pairing disease-awareness content with materials that explain cortisol-related symptoms and treatment paths. This matters in rare disorders: Cushing syndrome is often delayed or missed, and Corcept has said more than 40,000 people in the U.S. may be affected, so early recognition can lift diagnosis rates.
- Targets delayed diagnosis
- Explains symptoms and care paths
- Supports both patients and physicians
Physician-Led Promotion Powers Corcept’s Rare-Disease Growth
Corcept Therapeutics Incorporated’s promotion is physician-led and evidence-heavy, centered on endocrinology and oncology congresses, peer-reviewed data, and disease-awareness content for Cushing syndrome. That fits a rare market with delayed diagnosis and a limited prescriber base. In 2025, Company revenue was $611.6 million, supporting ongoing medical education and pipeline promotion.
| Promotion lever | 2025 signal |
|---|---|
| Congress data | Clinical updates for doctors |
| Education | Patient and physician awareness |
| Investor updates | SEC and earnings communication |
| Scale | $611.6 million revenue |
Price
Branded specialty-drug pricing
Korlym is a branded specialty drug for Cushing syndrome, so Corcept Therapeutics Incorporated prices it far above generic pills. Specialty medicines often carry annual costs above $100,000, and Korlym’s price reflects its narrow endocrine use, clinical benefit, and orphan-style market position.
Payer-dependent reimbursement
Corcept Therapeutics Incorporated uses payer-dependent reimbursement because patient cost can swing sharply with insurance coverage. For its rare-disease use case, access often needs prior authorization, so payer approval can decide whether therapy is filled at all. That makes reimbursement as important as list price, especially when copays and plan rules drive the real out-of-pocket cost.
Out-of-pocket varies by plan
For Corcept Therapeutics Incorporated, out-of-pocket costs vary by insurer, deductible, copay, and prior-authorization rules, so two patients can pay very different amounts for the same prescription. This is common for specialty oral medicines, where coverage design often drives the final bill more than the list price. Patients should check their plan’s formulary and cost-sharing details before filling the prescription.
Net price after discounts
Corcept Therapeutics Incorporated’s realized revenue is driven by gross-to-net deductions, so rebates and commercial discounts can materially cut the price it actually keeps. In U.S. specialty drugs, net price is usually well below list price, especially when insured patients use pharmacy benefit managers and prior authorization. That means realized pricing is more important than headline list price.
- Rebates lower realized revenue.
- Net price trails list price.
- Specialty coverage raises discounts.
Premium value in rare disease
Korlym sits in the rare-disease lane, where premium pricing is standard because Cushing’s syndrome has few treatment options and high unmet need. That support is real: Cushing’s syndrome is estimated to affect about 40,000 people in the U.S., so Corcept Therapeutics can price to the therapy’s clinical value, not just volume.
- Rare disease supports premium pricing
- Few approved alternatives raise value
- Pricing tracks unmet Cushing’s need
Korlym's Premium Price Reflects a Rare Disease Market
Corcept Therapeutics Incorporated prices Korlym as a premium orphan drug, with specialty therapy costs often above $100,000 a year. In Cushing’s syndrome, limited alternatives and about 40,000 U.S. patients support that price. Real revenue still falls after rebates, payer discounts, and prior authorization.
| Price driver | Data point |
|---|---|
| U.S. patient base | About 40,000 |
| Specialty annual cost | Above $100,000 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.